Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIb, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Pharmacokinetics of Glycopyrrolate Inhalation Solution Over 1 Week in Subjects With COPD

NCT06545500 is registered in ClinicalTrials.gov with Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA as lead sponsor.

NCT NCT06545500
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06545500 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIb, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Pharmacokinetics of Glycopyrrolate Inhalation Solution Over 1 Week in Subjects With COPD
Lead sponsor
Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Phase
Phase 2
Overall status
Completed
Start date
August 16, 2024
Completion date
January 8, 2025
Enrollment
46 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

chronic obstructive pulmonary disease